Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 748

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 748
---
 On June 1, 2023, Clinilabs entered into a start -upagreement with us. On December 4, 2023, we received five credit notes and two invoices from Clinilabs pursuant to services performed by Clinilabs under the start -upagreement. Clinilabs demanded $793,112.46 from us for unpaid service fees. CoreRX, Inc. On December 11, 2023, we received a notice alleging several causes of action, including a failure to remit payment for services rendered by CoreRX. On December 11, 2023, we and CoreRX agreed to a structured payment plan in which we agreed to pay CoreRX a total amount of $1,007,700.50. Dividends We have never declared or paid any cash dividends on our common shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then -existingconditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. Annex F-93 Under Swiss law, we may only pay dividends if we have sufficient distributable profits brought forward from the previous business years (“Gewinnvortrag”), or if we have distributable reserves (“frei verfügbare Reserven”), each as evidenced by our audited stand -alonestatutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have been deducted. Furthermore, the shareholders may resolve to pay an interim dividend (“ Zwischendividende”) if we have sufficient distributable profits based on an interim account. The provisions applicable for dividends are also applicable for the interim dividends. Under our amended and restated articles of association and in accordance with Swiss law, only our shareholders have the power to approve the payment of any dividends. B. Significant Changes. No significant change, other than as otherwise described in this annual report, has occurred in our operations since the date of our financial statements included in this annual report. ITEM 9. THE OFFER AND LISTING. A. Offer and Listing Details Since January 30, 2021, our common shares and Warrants trade on Nasdaq under the symbols “NLSP” and NLSPW,” respectively. B. Plan of Distribution Not applicable. C. Markets Our common shares and Warrants trade on